The pathophysiology of myeloproliferative disorders is based on the presence of certain genetic mutations. A majority of the cases of PV are accompanied by Janus kinase-2 (JAK-2) mutations, mainly the JAK2V617F mutation [1]. This evidence concerns the gene JAK2 and acquired polycythemia vera.